PHA-767491

• Description:

  PHA-767491 is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.

• Product Name Alternative:

  CAY10572

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pha-767491.html

• Purity:

  99.97

• Solubility:

  DMSO : 15.38 mg/mL (ultrasonic; adjust pH to 2 with 1 M HCL)

• Smiles:

  O=C1C2=C(NC(C3=CC=NC=C3)=C2)CCN1

• Molecular Formula:

  C12H11N3O

• Molecular Weight:

  213.24

• Precautions:

  H315, H319, H320

• References & Citations:

  [1]Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9 (11) :e113300.|[2]Li W, et al. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15 (3) :196-204.|[3]Erbayraktar Z, et al. Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int. 2016 Nov 18;16:88.|[4]Montagnoli A, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4 (6) :357-65.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK1; CDK2; CDK5; CDK9

• Citation 01:

  Acta Pharmacol Sin. 2022 Apr;43 (4) :1033-1045.|Nat Commun. 2024 Dec 5;15 (1) :10594.|Autophagy. 2022 Aug;18 (8) :1879-1897.|Sci Rep. 2021 Mar 8;11 (1) :5374.

• CAS Number:

  [845714-00-3]